Veradermics director-linked entities sell 100,000 shares
Entities associated with Veradermics, Inc director John W. Childs reported selling a total of 100,000 shares of Veradermics common stock on August 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Entities associated with Veradermics, Inc director John W. Childs reported selling a total of 100,000 shares of Veradermics common stock on August 12, 2026. The shares were held indirectly through the John W. Childs 2013 Revocable Trust and J.W. Childs Associates (FL), L.P., with prices based on weighted-average sale ranges.
Insights
Analyzing...
Insider Trade Summary
Net Seller: 100,000 shares
Net Sell
4 txns
Insider
CHILDS JOHN W
Role
Director
Sold
100,000 shs ($10.71M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 15,000 | $106.14 | $1.59M |
| Sale | Common Stock F3, F2 | 80,000 | $107.23 | $8.58M |
| Sale | Common Stock F2 | 5,000 | $108.24 | $541K |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,102,006 shares (Indirect, See Footnote)
Footnotes (4)
- F1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.77 to $106.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2. Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee of the John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
- F3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.04 to $107.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. Shares held by J.W. Childs Associates (FL), L.P. John W. Childs 2013 Revocable Trust is the sole owner of J.W. Childs Associates (FL), L.P. The Reporting Person, a member of the board of directors of the Issuer, is Trustee of John W. Childs 2013 Revocable Trust and may be deemed to hold voting and dispositive power with respect to these securities.
Key Figures
Shares sold (block 1): 15,000 shares at $106.14 per share
Shares sold (block 2): 80,000 shares at $107.23 per share
Shares sold (block 3): 5,000 shares at $108.24 per share
+1 more
4 metrics
Shares sold (block 1)
15,000 shares at $106.14 per share
Indirect sale of Veradermics common stock on 2026-08-12, weighted-average price
Shares sold (block 2)
80,000 shares at $107.23 per share
Indirect sale of Veradermics common stock on 2026-08-12, weighted-average price
Shares sold (block 3)
5,000 shares at $108.24 per share
Indirect sale of Veradermics common stock on 2026-08-12
Total shares sold
100,000 shares
Aggregate non-derivative common stock sales reported for 2026-08-12
Key Terms
weighted average price, indirect, revocable trust, dispositive power
4 terms
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect financial
"All reported sales were indirect. Shares were held by the John W. Childs 2013 Revocable Trust"
revocable trust financial
"Shares held by the John W. Childs 2013 Revocable Trust. The Reporting Person is Trustee"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
dispositive power financial
"may be deemed to hold voting and dispositive power with respect to these securities"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Veradermics (MANE) report for John W. Childs?
Veradermics reported that entities associated with director John W. Childs sold 100,000 shares of common stock on August 12, 2026. The transactions were reported as indirect sales through a revocable trust and a limited partnership.
Were the Veradermics (MANE) insider sales by John W. Childs direct or indirect?
All reported sales were indirect. Shares were held by the John W. Childs 2013 Revocable Trust and J.W. Childs Associates (FL), L.P., over which Childs, as trustee, may be deemed to have voting and dispositive power.
On what date did the Veradermics (MANE) insider transactions occur?
The reported insider transactions occurred on August 12, 2026. On that date, entities associated with director John W. Childs executed three separate indirect sales of Veradermics common stock at different weighted-average prices.
AI-generated analysis. How Rhea-AI works. Not financial advice.
